CMPS COMPASS Corp: Long-Term Debt to Capital Coefficient

Symbol and logo of brand COMPASS Corp (CMPS)

COMPASS Pathways plc (CMPS) is developing innovative psilocybin-based depression treatments, leveraging patent protection to establish premium pricing within its niche. However, business expansion is hindered by the requirement for direct physician involvement in therapy, which limits process automation. Drug logistics are strictly regulated, and the 0.67 metric complements the analysis, which this chart's market price visualizes.

CMPS - COMPASS Pathways PLC Long-Term Debt to Equity over the range 07/04/2022 - 10/27/2026

Comprehensive metric breakdowns and analytics for COMPASS Pathways plc (CMPS)

- price and consensus price forecast:
Quote Chart COMPASS Pathways PLC|CMPS - Analyst Consensus Forecast
- market capitalization data:
Market Value COMPASS Pathways plc|CMPS - Enterprise Value
- book capitalization data:
Book Value per Share COMPASS Pathways|CMPS - Company Book Value|Market Value to Book Value compasspathways.com|CMPS - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio COMPASS Pathways plc|CMPS - Long-Term Debt to Capital|Short-Term Debt to Capital compasspathways.com|CMPS - Company Total Debt|Debt to Net Assets Ratio COMPASS Pathways plc
Initial company analysis:COMPASS Pathways PLC
Core merchandise of COMPASS Pathways plc

The stability of synthetic compound supply chains for clinics confirms the operational resilience of COMPASS Pathways plc (CMPS), which, combined with the long-term debt financial leverage ratio on GURU.Markets, allows for an assessment of indebtedness risk. The ratio of liabilities with a maturity of over one year to equity determines the company's dependence on external financing, where low values guarantee survival during market shocks.

Competitors of COMPASS Pathways plc (CMPS)

Long-Term Liabilities to Equity Alkermes PLC|Avadel Pharma (AVDL) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient atai (ATAI)|Long-Term Debt to Capital GHRS (GH Research PLC)|mindmed.co - Long-Term Debt to Capital|Long-Term Debt to Equity LB Pharmaceuticals (LBRX)|DRUG: Long-Term Debt to Capital Coefficient|VNDA (Vanda Pharmaceuticals Inc) - Long-Term Debt to Equity|Cybin (CYBN) - Long-Term Debt to Equity Ratio|ANRO (Alto Neuroscience, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital nrxpharma.com (NRXP)|Cingulate Inc. (CING) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient SILO (silopharma.com)|China Pharma Holdings, Inc. (CPHI) - Long-Term Debt to Equity|Clearmind Medicine, Inc. - Long-Term Liabilities to Equity|Long-Term Debt to Equity PBM (Psyence Biomedical Ltd.)|scisparc.com (SPRC) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio SEEL|Virpax Pharmaceuticals, Inc. (VRPX) - Long-Term Liabilities to Capital|Long-Term Debt to Capital KRTX